ADARx Pharmaceuticals Inc.’s Post

👉Targeting Lp(a): Can RNA Therapeutics Provide the Next Step in the Prevention of CVD? ☝️Modulation of apo(a) expression via LPA transcripts represents a promising target for RNA-based therapies, with numerous publications reporting on their beneficial effects in reducing Lp(a) levels and the associated CVD risk. This review aims to outline the current opportunities and challenges with RNA-based therapeutics targeting Lp(a) 🔓Open access https://lnkd.in/dJMKxbpF European Atherosclerosis Society

🗞 IN THE NEWS: In a clinical trial at NIH’s National Cancer Institute (NCI), researchers tested the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (called ViPOR) in 50 patients with DLBCL, the most common type of lymphoma. The treatment shrank tumors substantially in 26 of 48 (54%) evaluable patients, with 18 (38%) of those patients’ tumors disappearing entirely, known as a complete response. At two years, 36% of all patients were alive and 34% were free of disease. These benefits were seen mainly in people with two specific subtypes of DLBCL. ➡ Read more in this piece by MedPage Today: https://lnkd.in/eK75QQyd Additional outlets that have covered ViPOR include Healio, European Pharmaceutical Review, HealthDay News, Clinical Trials Arena, etc. #CancerResearch #Lymphoma #ClinicalTrial #Health #Medicine

From innovative cancer therapy to menopause: How Defence Therapeutics, Bayer and NVIDIA are reshaping the medical landscape #Biotechnology #Pharma #DefenceTherapeutics #Bayer #Nvidia https://lnkd.in/eNHfzNR5

Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson in the Proactive studio ahead of a presentation of the results of its PTX-100 Phase 1b study at the 15th Annual T-Cell Lymphoma Forum (TCLF) in California from June 6 to 8. The Phase 1b study targeted patients with relapsed and refractory T-cell #lymphomas (r/r TCLs) and successfully met its primary objectives of demonstrating safety and determining pharmacokinetics and pharmacodynamics. Additionally, the study showed a promising preliminary efficacy with a 45% overall response rate, where five out of 11 evaluable patients responded positively to the treatment. Watch at #Proactive #ProactiveInvestors #Biotech #Biopharmaceutcials #Oncology #TCellLymphoma https://lnkd.in/epVKef5J

Revolutionize IBD Treatment: Human Antibody Library for Next-Gen Therapeutics Struggling to develop novel IBD therapies? Bypass the starting block. Our human antibody library offers a springboard for powerful, targeted treatments. Let's assemble the future of IBD care, together. #IBD #AntibodyDiscovery #NextGenTherapies

Chimeric Therapeutics, a clinical-stage cell therapy company, announced the reopening of its Phase 1B study on Thursday, focusing on advancing cancer research. This study is a critical step in evaluating the safety and efficacy of their innovative cell therapy treatments. By resuming this trial, Chimeric Therapeutics aims to gather essential data that could lead to groundbreaking advancements in cancer treatment, ultimately improving patient outcomes and offering new hope for those battling the disease. #ChimericTherapeutics #CellTherapy #CancerResearch #Phase1BStudy #ClinicalTrials #CancerTreatment #MedicalResearch #InnovativeTherapies #Biotech #HealthcareInnovation #Oncology #CancerCure #PatientCare #ResearchAndDevelopment #MedicalBreakthroughs #LifeSciences #HealthTech #CancerScience #ClinicalResearch #Biotechnology

Artiva Biotherapeutics is looking to raise up to $135 million from an Initial Public Offering (IPO) to fund clinical trials for its leading allogeneic natural killer (NK) cell therapy. The San Diego-based company revealed these plans in a recent Securities and Exchange Commission filing, with expectations of selling 8.7 million shares priced between $14 and $16 each 💰 💵 The major focus for the proceeds will be on advancing the clinical development of AlloNK, a non-genetically modified, cryopreserved NK cell therapy. Currently, AlloNK is being tested in a phase 1 trial for lupus nephritis alongside Roche's Rituxan or Gazyva. It's also part of another study that spans multiple autoimmune indications. By the first half of 2025, we should see some promising data readouts 📉 #Biotechnology #ArtivaBiotherapeutics #ClinicalTrials #NKCellTherapy #IPO #LifeScience #ElixirAssociates #StaffingPartner

Combining the power of hiPSCs with deep understanding of drug discovery.

The key role of integrins in regulating cell-cell adhesion, migration, and motility has made this extensive family of membrane proteins attractive therapeutic targets.  To provide a preclinical platform for evaluating novel therapeutics targeting integrins, our team has designed several humanized integrin models. Check out our B-hITGA2 Mice (https://lnkd.in/epAiJkDR)  and B-hITGB7 Mice(https://lnkd.in/e9pav29Q). #mousemodel #tumormodel #immunecheckpoint #humanizedmodel #preclinicalresearch #invivo #therapeutics #immunotherapy #antitumortherapy #cancertherapy #cancerresearch

Major strategy shift for allogeneic CAR-T leader Allogene Therapeutics MedicineToMarket.com has learned that Allogene Therapeutics is implementing pivotal changes to the clinical plans and organizational structure supporting their off-the-shelf CAR-T pipeline. The most notable update is Allogene pivoting the Phase 3 trial for their anti-CD19 CAR-T candidate from 3rd line to 1st line large B-cell lymphoma. By targeting frontline treatment, the company can tap into a larger market not addressed by autologous CAR-Ts like Yescarta or Breyanzi. However, this revised approach means efficacy data likely won't come until 2026 rather than sooner. It's a bold bet that allogeneic development should diverge from the path paved by autologous therapies. #pharma #biotech #cartcelltherapy #jpm2024